ACM
ALNY icon

Ararat Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ararat Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,985
Closed -$5.47M – 20
2021
Q3 		$5.47M Buy
28,985
+642
+2% +$120K 1.93% 16
2021
Q2 		$4.8M Buy
28,343
+2,553
+10% +$374K 2.21% 18
2021
Q1 		$3.64M Hold
25,790
– – 1.98% 17
2020
Q4 		$3.35M Buy
+25,790
New +$3.44M 1.94% 18

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Ararat Capital Management's ALNY Position: Q4 2021 in Review

Ararat Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 28,985 shares — an estimated $5.47M sold.

Ararat Capital Management first reported a position in ALNY in Q4 2020 and held it in 4 quarters. The position peaked at $5.47M in Q3 2021. 435 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Ararat Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ararat Capital Management sold 28,985 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $5.47M.
  • Ararat Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Ararat Capital Management's Alnylam Pharmaceuticals position peaked at $5.47M in Q3 2021.
  • 435 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Ararat Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.